PERFUSION MEDICAL LLC
Herndon, VA · Medtech · Private
Intravenous solution for treating septic and hemorrhagic shock
perfusionmedical.com →- Grants
- $3.6M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $5.2M
- 4 awards · Defense
- #121 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Polymer use in Preservation of Tissue Perfusion to Address Sepsis | $256,492 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Polymer use in Preservation of Tissue Perfusion to Address Sepsis | $256,492 | |
| Federal grant· 1 of 2 same day | Department of Defense · Phase I · The Mayo Clinic and Perfusion Medical: PEG-20k/8k - A Patented Intravenous Solution to Treat Septic Shock | $74,948 | |
| Federal grant· 2 of 2 same day | Department of Defense · Phase I · The Mayo Clinic and Perfusion Medical: PEG-20k/8k - A Patented Intravenous Solution to Treat Hemorrhagic Shock | $74,948 | |
| Federal grant | Department of Defense · Phase II · IND-enabling Studies of PM-208: A Novel Pre-hospital Anti-Shock Therapeutic | $2,986,773 | |
| Federal contract | Department of Defense · Research And Development Of Optimal Dosing And Formulation Of PM-208 (PEG-20K/8K) For Af Field Use | $1,799,322 | |
| Federal contract | Department of Defense · Polyethylene GLYCOL-20K/8K (PEG-20K/8K): A Patented Intravenous Solution In Uncontrolled Hemorrhage | $109,917 | |
| Federal contract | Department of Defense · Human Clinical Trial For Safety Of PM-208 Anti-shock Drug | $1,799,970 | |
| Federal contract | Department of Defense · Ind-enabling Studies Of PM-208: A Novel Pre-hospital Anti-shock Therapeutic | $1,499,773 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 118 | MOTION CONTROL, INC | $5.4M | — |
| 119 | VIA THERAPEUTICS, LLC | $5.4M | — |
| 120 | KERICURE INC. | $5.3M | $310K |
| 121 | PERFUSION MEDICAL LLC | $5.2M | — |
| 122 | Gate Scientific, Inc. | $5.1M | — |
| 123 | AA PLASMA LLC | $5.0M | — |
| 124 | DAXOR CORPORATION | $4.9M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.